SEC Comment Letter 0000000000-24-000601 to Ernexa Therapeutics Inc. (ERNA)
Ernexa Therapeutics Inc.
Date: Jan. 17, 2024 · CIK: 0000748592 · Accession: 0000000000-24-000601
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-276493
Letter
United States securities and exchange commission logo January 17, 2024 Sanjeev Luther Chief Executive Officer Eterna Therapeutics Inc. 1035 Cambridge Street, Suite 18A Cambridge, MA 02141 Re:Eterna Therapeutics Inc. Registration Statement on Form S-3 Filed January 12, 2024 File No. 333-276493 Dear Sanjeev Luther: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Lauren Hamill at 303-844-1008 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Jeffrey Schultz
Show Raw Text
United States securities and exchange commission logo
January 17, 2024
Sanjeev Luther
Chief Executive Officer
Eterna Therapeutics Inc.
1035 Cambridge Street, Suite 18A
Cambridge, MA 02141
Re:Eterna Therapeutics Inc.
Registration Statement on Form S-3
Filed January 12, 2024
File No. 333-276493
Dear Sanjeev Luther:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Lauren Hamill at 303-844-1008 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Jeffrey Schultz